In a significant development for India’s pharmaceutical regulatory landscape, the Drugs Technical Advisory Board (DTAB) has reaffirmed its position to include all antimicrobial drugs under the definition of “New Drugs” as per the New Drugs and Clinical Trials Rules, 2019.
The decision was taken during the 93rd meeting of DTAB held on February 16, 2026, at FDA Bhawan, New Delhi, conducted in a hybrid format. The board reviewed and approved the Action Taken Report (ATR) from its previous (92nd) meeting held on April 24, 2025.
One of the key highlights of the discussion was the reconsideration of the proposal to bring all antimicrobials under stricter regulatory control by classifying them as “New Drugs.” While the matter had been revisited upon request, the Board, after detailed deliberations, stood firm on its earlier recommendation and agreed in principle to move forward with the inclusion.
This move is expected to have far-reaching implications for pharmaceutical companies manufacturing antimicrobial drugs, as classification under “New Drugs” typically requires additional regulatory approvals, clinical data, and oversight.
However, in a balanced approach, DTAB has recommended that the proposed change should be implemented prospectively. This means that existing license holders will not be burdened with new regulatory requirements and can continue manufacturing, selling, and distributing their products without any additional compliance obligations.
To ensure clarity and smooth implementation, the Board also advised that a detailed proposal outlining the licensing pathway should be circulated among all members. This is aimed at providing a structured framework for transitioning to the new regulatory requirement.
The recommendation reflects India’s growing focus on strengthening antimicrobial regulation, a critical step in addressing concerns like antimicrobial resistance and ensuring drug safety and efficacy.
Further developments are expected once the detailed proposal is finalized and formally notified.
